Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06442462
PHASE2

Study of SPG302 in Adults With Schizophrenia

Sponsor: Spinogenix

View on ClinicalTrials.gov

Summary

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

Official title: A Randomized, Placebo-controlled, Double-blind Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacodynamics of SPG302 in Adult Participants Diagnosed With Schizophrenia

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2024-08-01

Completion Date

2026-03

Last Updated

2026-02-06

Healthy Volunteers

No

Conditions

Interventions

DRUG

SPG302

small synthetic molecule

DRUG

Placebo

Placebo

Locations (3)

CenExel CNS

Garden Grove, California, United States

Box Hill Hospital - Eastern Health

Box Hill, Victoria, Australia

Multidisciplinary Alfred Psychiatry Research Centre (MAPrc)

Melbourne, Victoria, Australia